Why Black Diamond Therapeutics, Inc.’s (BDTX) Stock Is Up 5.15%
As of Wednesday, September 02, Black Diamond Therapeutics, Inc.’s BDTX share price has surged by 5.15%, which has investors questioning if this is right time to sell.Jenna Brashear
Stock Evaluator: Black Diamond Therapeutics, Inc. (BDTX)
Black Diamond Therapeutics, Inc. BDTX
$2.10
-0.05
-2.10%
September 3, 2026 11:15:07 AM
EST
Volume: 83,322
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Why Black Diamond Therapeutics, Inc.’s (BDTX) Stock Is Up 5.83%
As of Wednesday, August 19, Black Diamond Therapeutics, Inc.’s BDTX share price has surged by 5.83%, which has investors questioning if this is right time to sell.Michael Rose
Why Black Diamond Therapeutics, Inc.’s (BDTX) Stock Is Up 6.70%
As of Thursday, August 06, Black Diamond Therapeutics, Inc.’s BDTX share price has surged by 6.70%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Black Diamond Therapeutics, Inc.’s (BDTX) Stock Is Down 5.25%
As of Friday, July 31, Black Diamond Therapeutics, Inc.’s BDTX share price has dipped by 5.25%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Black Diamond Therapeutics, Inc.’s (BDTX) Stock Is Down 5.97%
As of Wednesday, July 29, Black Diamond Therapeutics, Inc.’s BDTX share price has dipped by 5.97%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | BDTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $123.0 | $288.9 | 23% |
|
| Shares Out (Mil) | 57.4 | 54.0 | 51% |
|
| Institutional Ownership | 98.7% | 93.1% | 81% |
|
| Float (Mil) | 52.6 | 41.4 | 48% |
|
| Beta | 3.29 | 0.94 | 98% |
|
| Avg Daily Volume (000s) | 580 | 480 | 62% |
|
| Price Change (52-week) |
(23.6%) | 59.9% | 28% |
|
| Growth | BDTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | 18.5% | (10.1%) | 70% |
|
| EPS (5yr) | 17.0% | 15.9% | 62 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 40.5% | (15.6%) | 91% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | ($0.055) | ($0.567) | ($1.000) | |
| Month Ago EPS | ($0.060) | ($0.632) | ($1.162) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.060) | ($0.632) | ($1.162) | |
| Year/Year Chg | (68.2%) | (245.4%) | (331.8%) | |
| Financials | BDTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($43) | ($43) | 17% |
|
| EPS (TTM) | ($0.745) | ($1.500) | 24% |
|
| Operating Cash Flow (TTM) (Mil) | ($33) | ($31) | 12% |
|
| Net Cash Flow (TTM) (Mil) | ($11) | $2 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $13 | $4 | 30% |
|
| Enterprise Value (Q1) (Mil) | $33 | $190 | 14% |
|
| Valuation | BDTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.28 | 2.84 | 32% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BDTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (29.2%) | (47.7%) | 17% |
|
| ROE | (37.2%) | (55.0%) | 18% |
|
| Liabilities to Assets | 23.1% | 29.6% | 16% |
|
| F-Score | 2 | 3 | 7% |
|
Black Diamond Therapeutics, Inc. did not pass any screens on 9/2/2026.
